Invenomic Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Archer Daniels Midland
ADM
|
+$35.4M |
| 2 |
TD Synnex
SNX
|
+$24M |
| 3 |
3M
MMM
|
+$23.6M |
| 4 |
Melco Resorts & Entertainment
MLCO
|
+$17.8M |
| 5 |
OPLN
Openlane
OPLN
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
QuidelOrtho
QDEL
|
+$37.1M |
| 2 |
Comcast
CMCSA
|
+$36.9M |
| 3 |
Illumina
ILMN
|
+$32.3M |
| 4 |
Citigroup
C
|
+$29.7M |
| 5 |
Viatris
VTRS
|
+$22.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.32% |
| 2 | Consumer Discretionary | 17.17% |
| 3 | Energy | 12.32% |
| 4 | Healthcare | 9.35% |
| 5 | Consumer Staples | 8.66% |
Similar funds
Invenomic Capital Management's Q1 2024 Portfolio in Review
As of Q1 2024, Invenomic Capital Management held 207 positions worth $1.88B, down 14% from $2.19B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Invenomic Capital Management withdrew a net $314M in Q1 2024, closing 62 positions and reducing 46 holdings. Its most notable exit was QuidelOrtho, an estimated $37.1M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Consumer Discretionary and Energy.
Against the trend, Invenomic Capital Management opened a new position in Archer Daniels Midland worth $37.9M.
- Invenomic Capital Management's largest Q1 2024 buy was Archer Daniels Midland: 603,681 shares worth $37.9M.
- Invenomic Capital Management added most to 3M in Q1 2024, an estimated $23.6M increase.
- Invenomic Capital Management's biggest Q1 2024 reduction was Illumina, cutting an estimated $32.3M.
- Invenomic Capital Management fully exited QuidelOrtho in Q1 2024, selling an estimated $37.1M.
- Invenomic Capital Management's ten largest holdings make up 24% of its $1.88B portfolio in Q1 2024.
- Invenomic Capital Management opened 35 new positions and closed 62 in Q1 2024.
- Invenomic Capital Management's portfolio value fell 14% quarter-over-quarter to $1.88B.
Based on Invenomic Capital Management's 13F filing for Q1 2024, filed 15 May 2024.